Welcome to RespiratoryXchange for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK).
This website is an international information resource intended for international healthcare professionals outside the US and the UK who are interested in medical information on respiratory disease such as chronic obstructive pulmonary disease (COPD) and asthma.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product labels of the mentioned medicinal products may not be the same in different countries. Please refer to your local prescribing information for full details on the respective medicinal products.
By clicking on the link above you are declaring and confirming that you are a healthcare professional outside the US and UK and have read and understood this disclaimer.
Explore the data on improving physical activity for COPD patients. Data presented at the ERS Congress 2016 showed that with optimal bronchodilator therapy and exercise training, the exercise capacity of COPD patients can be improved. Read this short article to gain insight into the results on enhancing exercise tolerance and physical activity from the PHYSACTO® study.
Burden of respiratory disease, Developments in Respiratory, Treatment approaches
You're now leaving our website...
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.